Oxford, UK – 17 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, is pleased to announce that it has appointed Jefferies Hoare Govett as Sole Corporate Broker… Read More
Oxford, UK – 12 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, announces today that Dr Paul Blake will leave the Group when his current contract expires… Read More
Oxford, UK – 6 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:Oxford Biomedica), a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term… Read More
Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen again. The Recording will be available four… Read More
London, UK – 26 April 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:Oxford Biomedica), a leading gene and cell therapy company, today announces the appointment of Stuart Henderson as a non-executive Director of the Company and… Read More
Oxford, UK – 7 March 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announced a new and expanded collaboration with Immune Design Corp. (“Immune Design”), a… Read More
Oxford, UK – 29 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces today that the Group has initiated work on a second Chimeric Antigen Receptor… Read More
– New manufacturing facility fully operational – Creates extra capacity for wholly-owned pipeline, Novartis partnership and other new potential customers… Read More
Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director,… Read More
From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver… Read More
Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, is pleased to announce the following business update. Read More